Prevention of Human Immunodeficiency Virus Type 1 Trans-mission by Pharmaceuticals Targeted to Host Proteins Re-quired for Virus Infection? Consideration of Farnesyl Thiosalicylic Acid, a Ras Inhibitor
- *Corresponding Author:
- Dr. A Robert Neurath, Virotech,
1496 Hemlock Farms, Hawley, PA 18428, USA,
Phone : (570) 775 7877 or (212) 529 4584,
E-mail : [email protected]
Received Date: November 25, 2009; Accepted Date: December 26, 2009; Published Date: December 26, 2009
Citation: Neurath AR, Lackman-Smith C (2009) Prevention of Human Immunodeficiency Virus Type 1 Transmission by Pharmaceuticals Targeted to Host Proteins Required for Virus Infection? Consideration of Farnesyl Thiosalicylic Acid, a Ras Inhibitor. J Antivir Antiretrovir 1: 072-075. doi: 10.4172/jaa.1000010
Copyright: © 2009 Neurath AR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recent success in defining the human immunodeficiency virus type 1 (HIV-1) – host cell protein interaction network has provided an opportunity for development of novel antiviral therapeutics targeted to host proteins required for virus infection. This expanded earlier successful development of antagonists for the cellular receptors (CD4) and co-receptors (CCR5 or CXCR4) involved in virus attachment. Induction of the G-alphaq signaling cascade by the HIV-1 envelope is required for virus entry, and it’s blocking prevented HIV-1-mediated membrane fusion and initiation of infection. One of the blockers, the Ras inhibitor S-trans, trans-farnesylthiosalicylic acid (FTS), was reported to interfere with HIV-1 infection. Since FTS appears to have an established safety record and is being evaluated (as Salirasib, oral) in phase II human clinical trials for treatment of lung cancer, it was of interest to evaluate the potential of FTS as a topical microbicide for prevention of sexual transmission of HIV-1. Data shown here indicated that this compound did not meet the criteria of an established screening algorithm for evaluation of topical microbicides. Nevertheless, the possibility remains to be explored that FTS (especially when used in combination with other anti-HIV drugs) might be useful in sustained pre-exposure prophylaxis to prevent HIV-1 transmission.